Allogene Therapeutics, Inc. (NASDAQ: ALLO)

Allogene Therapeutics, Inc., often recognized by its stock symbol ALLO, is a company that operates within the immuno-oncology industry. This clinical-stage business is dedicated to the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases.

Allogene's primary business activities revolve around the creation of engineered T cells designed to target and eliminate cancer cells in patients or pathogenic autoreactive cells in patients with autoimmune disorders. The company's approach is unique as it involves engineering healthy donor T cells to create an inventory of off-the-shelf products. This method is designed to overcome the limitations of autologous T cell therapies, which require individualized manufacturing and can take a considerable amount of time to deliver.

The company's revenue generation is primarily based on its allogeneic CAR T cell product candidates. These include cema-cel, ALLO-316, and ALLO-329. Cema-cel, the company's lead product candidate, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the surface of B cells. It is being developed for the treatment of B cell lymphoma and chronic lymphocytic leukemia. ALLO-316, another product candidate, targets CD70, a protein expressed on the surface of certain cancer cells, and is being developed for the treatment of renal cell carcinoma. ALLO-329, the third product candidate, targets both CD19 and CD70 and is being developed for the treatment of autoimmune diseases.

Allogene's position within the industry is strengthened by its proprietary manufacturing process, experienced management team, and strong intellectual property position. The company's management team has significant experience in immuno-oncology and has led the development and approval of several CAR T cell therapies, including Yescarta and Kymriah.

In terms of its customers, Allogene has partnered with several leading biopharmaceutical companies, including Pfizer and Cellectis, to develop and commercialize its allogeneic CAR T cell product candidates. The company has also established relationships with several leading hospitals and research institutions to support its clinical trials.

The brand names and/or trade names of its products and services include cema-cel, ALLO-316, and ALLO-329. Each of these product candidates represents a significant step forward in the treatment of various diseases, demonstrating Allogene's commitment to innovation and patient care.